TY - JOUR T1 - Multidisciplinary analysis of evolution based Abiraterone treatment for metastatic castrate resistant prostate cancer JF - medRxiv DO - 10.1101/2021.11.30.21267059 SP - 2021.11.30.21267059 AU - Jingsong Zhang AU - Jessica J. Cunningham AU - Joel S. Brown AU - Robert A. Gatenby Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/02/2021.11.30.21267059.abstract N2 - Background We present a multidisciplinary approach to clinical trial design and analysis in a pilot study (NCT02415621) in which evolution-based mathematical models guide patient-specific dosing for Abiraterone treatment in men with castrate resistant metastatic prostate cancer.Methods Abiraterone plus prednisone were administered intermittently based on an evolutionary mathematical model. Outcomes are compared to historical controls and a matched contemporaneous cohort who met trial eligibility but received SOC dosing. Longitudinal cohort data allowed modification of pre-trial model parameter estimates. Model simulations of each patient using updated parameters critically evaluated trial design.Results Trial patients, on average, received no abiraterone during 59% of time on treatment. Median Time to Radiographic Progression (TTP) was 30.4 months compared to 14.3 months in the contemporaneous SOC group (p<0.001). All patients in the SOC group have progressed but 4 in the adaptive cohort remain on treatment at >1800 days. Longitudinal trial data found the competition coefficient ratio (αRS/αSR) of sensitive and resistant populations, a critical factor in intratumoral evolution, was 2 to 3-fold higher than pre-trial estimates. Computer simulations using the corrected parameter unexpectedly demonstrated optimal cycling can reduce the resistant cells. Longitudinal data from 4 trial patients who remain on treatment are consistent with model predictions. Modeling results predict protocol changes that will allow similar outcomes in most patients.Conclusions Administration of abiraterone using evolution-based mathematical models decreased drug dosing and increased radiographic TTP. Integration of mathematical models into trial design identifies novel insights into key treatment parameters and provides optimization strategies for follow-up investigations.Article Summary supplemental sections outline the methodology for parameter estimates from trial data, computer simulations, and comparison of simulation results and actual clinical data in every patient in both cohorts.Statement of Translational Relevance Integration of evolution-based mathematical models significantly increased TTP in abiraterone therapy for mCRPC. This multidisciplinary approach represents a novel clinical trial strategy in which the treatment protocol is framed mathematically, clinical data then refines model parameterization, and simulations using the updated model predict alternative strategies to improve outcomes. Here we demonstrate the mathematical models used to design the trial can also produce novel analytic approaches. By using longitudinal trial data, key model parameters can be refined. Simulations using the updated model can then be applied to every patient in the trial. Finally, additional simulations demonstrate alternative protocols that could improve results. These analyses demonstrate evolution-based approaches may allow consistent long-term control in patients with metastatic prostate cancer.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02415621Funding StatementThis work was supported by the James S. McDonnell Foundation grant Cancer therapy: Perturbing a complex adaptive system grants from the Jacobson Foundation NIH/National Cancer Institute (NCI) R01CA170595, Application of Evolutionary Principles to Maintain Cancer Control (PQ21), and NIH/NCI U54CA143970-05 (Physical Science Oncology Network (PSON)) Cancer as a complex adaptive system. This work has also been supported in part by the Clinical Trials Core Facility at the H. Lee Moffitt Cancer Center and Research Institute an NCI-designated Comprehensive Cancer Center (P30-CA076292) and the European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 690817.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Moffitt Cancer Center gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -